Evidence map›Paper›PMID 18671663›Full record

ReviewExpert review of neurotherapeutics2008

Cell-based therapy in ischemic stroke.

David C Hess, Cesar V Borlongan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of neurotherapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Stem cell therapy as a promising approach for ischemic stroke treatment.Current research in pharmacology and drug discovery · 2024
    Review
  5. Review
  6. The circular RNANeural regeneration research · 2023
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

David C HessDepartment of Neurology, Medical College of Georgia, Augusta, GA 30912, USA. dhess@mail.mcg.edu
Cesar V Borlongan

Funding

Minocycline to Improve Neurologic Outcome (MINO Clinical Trial)R01NS055728 · NINDS · AUGUSTA UNIVERSITY · PI HESS, DAVID C. · 2007 to 2009
$1.6M
Stem Cells for Neonatal Hypoxic-Ischemic Brain InjuryR42NS055606 · NINDS · ATHERSYS, INC. · PI CARROLL, JAMES EDWIN · 2007 to 2010
$1.2M
TRANSPLANTATION OF MULTIPOTENT PROGENITOR CELLS IN STROKEU01NS055914 · NINDS · UNIVERSITY OF SOUTH FLORIDA · PI BORLONGAN, CESARIO V · 2008 to 2010
$700k
NINDS NIH HHS 1U01 NS 055914NINDS NIH HHS 2R42 NS055606NINDS NIH HHS R01 NS055728NINDS NIH HHS R42 NS055606NINDS NIH HHS U01 NS055914
6 · The paper itself

Abstract

Cell-based therapy for stroke represents a third wave of therapeutics for stroke and one focused on restorative processes with a longer time window of opportunity than neuroprotective therapies. An early time window, within the first week after stroke, is an opportunity for intravenously delivered bone marrow and perinatally derived cells that can home to areas of tissue injury and target brain remodeling. Allogeneic cells will likely be the most scalable and commercially viable product. Later time windows, months after stroke, may be opportunities for intracerebral transplantation of neuronally differentiated cell types. An integrated approach of cell-based therapy with early-phase clinical trials and continued preclinical work with focus on mechanisms of action is needed.

Indexed as

Brain IschemiaHumansStem Cell TransplantationStrokeTreatment Outcome

Identifiers

PMID18671663
PMCPMC2753686

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.